Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067405 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL1068890 | 0.98 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL1068891 | 0.98 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL11088300 | 0.86 | CA2 (0.35) | SMN1; SMN2TSHRCA2CA1 | |
| SCHEMBL11088304 | 0.86 | CA2 (0.35) | SMN1; SMN2TSHRCA2CA1 | |
| SCHEMBL11088312 | 0.86 | CA2 (0.35) | SMN1; SMN2TSHRCA2CA1 | |
| SCHEMBL15537131 | 0.83 | NPSR1 (0.40) | SMN1; SMN2ALDH1A1LMNAGAAPLA2G2A | |
| SCHEMBL15537128 | 0.83 | NPSR1 (0.40) | SMN1; SMN2ALDH1A1LMNAGAAPLA2G2A | |
| SCHEMBL16561939 | 0.81 | NPSR1 (0.41) | SMN1; SMN2ALDH1A1LMNAPLA2G2APLA2G5 | |
| SCHEMBL10811086 | 0.81 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1LMNAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8624033-B2 | Pleuromutilins and process for the preparation of pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2014-01-07 | — | — | US | disclosed |
| US-20130053571-A1 | PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2013-02-28 | — | — | US | disclosed |
| US-8334389-B2 | Process for the preparation of pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2012-12-18 | — | — | US | disclosed |
| EP-2069301-B1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2011-09-07 | — | — | EP | disclosed |
| EP-2272829-A2 | Process for the preparation of pleuromutilins | Nabriva Therapeutics AG (AT) | 2011-01-12 | — | — | EP | disclosed |
| US-20090253748-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2009-10-08 | — | — | US | disclosed |
| EP-2069301-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | Nabriva Therapeutics Forschungs GmbH (AT) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008040043-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2008-04-10 | — | — | WO | disclosed |
| EP-1908750-A1 | Process for the preparation of pleuromutilins | Nabriva Therapeutics Forschungs GmbH (AT) | 2008-04-09 | — | — | EP | disclosed |
| EP-0421364-B1 | Pleuromutilins | BIOCHEMIE GMBH (AT) | 1995-06-21 | — | — | EP | disclosed |
| US-5284967-A | Pleuromutilins | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1994-02-08 | — | — | US | disclosed |
| US-5164526-A | Antitumor for pigs | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1992-11-17 | — | — | US | disclosed |
| EP-0421364-A2 | Pleuromutilins | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053571-A1 | PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | PLEC, MLN, PTMA | SMN1; SMN2 306/4885ALDH1A1 312/4885LMNA 2096/4885 |
| US-20090253748-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | PLEC, MLN, PTMA | SMN1; SMN2 176/4885ALDH1A1 182/4885LMNA 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.